OneSource Specialty Pharma Ltd Directors Report

Dear Shareholders,

Your directors take pleasure to present the 19 th Boards Report of OneSource Specialty Pharma Limited (the Company or OSPL or OneSource) prepared in line with the Companies Act, 2013 (Act) and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations). This report presents the Audited financial results (Consolidated and Standalone) and other developments in respect to the Company during the financial year ended March 31, 2026 (FY26 or Financial Year) and as on date of this report.

1. Financial Performance

The Company has prepared the Consolidated and Standalone Financial Statements for the financial year ended March 31, 2026, in accordance with the Indian Accounting Standards (Ind AS) as prescribed under the Companies Act, 2013 (Act).

Key Highlights (Consolidated Financials)

(In million except per share data)

Particulars	FY26	FY25
Revenue	14,216	14,449
EBITDA	3,042	4,665
EBITDA Margin (%)	21.4%	32.3%
Adjusted PAT 1	739	2,314
Adjusted EPS 1	6.5	21.4

1 Adjusted PAT and Adjusted EPS exclude exceptional items (FY26: _99m, FY25: _1,108m) and scheme related intangible amortisation (FY26: _1,378m, FY25: _1,413m).

2. Companys Performance

About the Company:

OneSource is a pure-play specialty pharmaceutical CDMO providing integrated development and manufacturing solutions across complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It operates five state-of-the-art facilities approved by global regulatory authorities with a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions.

Performance Highlights

FY26 was a year of focused execution and capability enhancement, strengthening the foundation for sustainable long-term growth across our specialty platforms.

Financial Snapshot y Full-year revenue declined marginally by 2% YoY, reflecting a softer second half impacted by delayed semaglutide approvals in Canada. y Full year EBITDA declined 35% YoY, reflecting a high MSA base in prior year and an elevated cost base in FY26 as the DDC facility ramped up. Managements Discussion and Analysis Report, which forms part of the Boards Report details the Companys operational and financial performance for the year.

3. Capital Structure a. Authorised Share Capital

Authorised Share Capital of the Company as at March 31, 2026 is 15,00,00,000 divided into 15,00,00,000 equity shares of 1 each. b. Issued, Subscribed, and Paid-up Share Capital

The movement in Issued, Subscribed, and Paid-up Share Capital of the Company during the year is as under:

Particulars	Number of Shares	Amount ()
April 1, 2025	11,44,36,021 equity shares of face value of 1.00 each	11,44,36,021
Additions during the year (consequent to ESOP exercise)
June 13, 2025	30,000 equity shares of face value of 1.00 each	30,000
August 04, 2025	59,195 equity shares of face value of 1.00 each	59,195
October 24, 2025	36,920 equity shares of face value of 1.00 each	36,920
December 09, 2025	23,000 equity shares of face value of 1.00 each	23,000
January 21, 2026	36,065 equity shares of face value of 1.00 each	36,065
March 31, 2026	11,46,21,201 equity shares of face value of 1.00 each	11,46,21,201

4. Dividend

The Company has reported a profit on a standalone basis during the year. However, in view of ongoing expansion plans and future capital requirements, the Board has not recommended any dividend for the financial year ended March 31, 2026. Dividend distribution policy is available on below link: https://www.onesourcecdmo.com/wp-content/ uploads/2025/01/Dividend-Distribution-Policy.pdf

5. Transfer to Reserves

Movement in reserves and surplus during the financial year ended March 31, 2026, is provided in the Statement of changes in equity included in the consolidated and standalone Financial Statements (Refer to Note 11B in the Consolidated as well as the Standalone Financial Statements).

6. Update on Corporate Actions

During the year under review and to the date of this Report, your Company has undertaken/ initiated the following key corporate actions:

Scheme of Arrangements

6.1 Scheme of Arrangement for acquisition of European CDMO business of SteriScience and anti-infective business from Brooks SteriScience.

The Board of Directors at their meeting held on September 26, 2025, approved a strategic transaction to strengthen the companys capabilities and capacity by acquiring the European CDMO business of Steriscience and anti-infective business from Brooks Steriscience.

The said transaction was intended to be achieved through a Scheme of Amalgamation amongst Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited and OneSource Specialty Pharma Limited and their respective shareholders (under section 230 to 232 read with section 234, section 52, section 66 of the Act and under section 210 read with section 212 of The Singapore Companies Act, 1967 and other applicable provisions of the Act, the Singapore Companies Act, 1967 and the rules framed thereunder).

The National Stock Exchange of India Limited and BSE Limited by their respective letters dated February 25, 2026 conveyed their No-objection /No Adverse Observation Letter, for the Scheme.

However, the Board of Directors at their meeting held on May 13, 2026, in the best interest of stakeholders decided to not pursue the transaction in the current form and revisit it following successful delivery of respective companies FY28 guidance.

6.2 Amalgamation of Stelis Pte. Limited with OneSource Specialty Pte. Limited, wholly owned subsidiaries of One Source Specialty Pharma Limited (the Company)

Stelis Pte. Limited (Stelis), Singapore a wholly owned subsidiary of the Company amalgamated with OneSource Specialty Pte. Limited (OneSource Specialty Pte.), Singapore another wholly owned subsidiary of the Company with effect from January 01, 2026 to simplify the existing corporate hierarchy, enhance operational efficiency, and eliminate redundant administrative, compliance, and legal costs. Since the transaction was undertaken between the wholly owned subsidiaries of the Company, there is no impact on a consolidated basis and on the shareholding pattern of the Company.

6.3 Striking off of the wholly owned subsidiary entity – Stelis Biopharma UK Private Limited

Stelis Biopharma UK Private Limited was struck off with effect from October 14, 2025, as there was no business activity and remained dormant since its incorporation on November 30, 2022.

7. Consolidated Accounts

The consolidated financial statements for the year ended March 31, 2026, pursuant to Section 129(3) of the Act, form part of this Annual Report.

8. Subsidiaries/Joint Ventures/Associates and Accounts of Subsidiaries

In accordance with Section 129 (3) of the Act, the Company has prepared a consolidated financial statements.

The Company has the following subsidiaries, joint ventures, and associate entities as at March 31, 2026:

S. No. Nature of Relationship	India	Overseas	Total
1 Wholly owned subsidiary	2	2	4
2 Step \u2013 down wholly owned subsidiary	-	2	2
3 Associate	-	-	-
4 Joint Venture	-	-	-
Total	2	4	6

List of Wholly Owned Subsidiaries: y Biolexis Private Limited, India y OneSource Specialty Pharma Inc, USA y OneSource Specialty Pte. Limited, Singapore y Strides Pharma Services Private Limited, India

Step-down wholly owned Subsidiaries: y Biolexis Pte. Ltd, Singapore - Biolexis Private Limited, India (Holding Company) y OneSource Softgels Pte. Ltd., Singapore (formerly known as Strides Softgels Pte. Ltd.) - Strides Pharma Services Private Limited, India (Holding Company A statement containing salient features of the financial statements of the Companys subsidiaries, as required in Form AOC 1 is enclosed as Annexure - 1 to this Report.

9. Employee Stock Option Scheme

The Company has Stock Option Plan viz., OneSource Specialty Pharma Limited: Employee Stock Option Scheme 2021 (ESOP Scheme).

A statement giving detailed information on stock options granted to Employees under the ESOP Scheme as required under Section 62 of the Act, read with Rule 12 of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 is enclosed as Annexure - 2 to this Report and the scheme is also available at website of the Company at below link: https://www.onesourcecdmo.com/wp-content/ uploads/2025/07/OneSource_ESOP-Scheme.pdf

10. Loans, Guarantees, and Investments

Details of loans, guarantees, and investments covered under Section 186 of the Act, form part of the notes to the financial statements provided in this Annual Report.

11. Public Deposits

The Company did not accept any public deposit during the year under review, as outlined in Chapter V of the Act and the corresponding Rules.

12. Credit Rating

The Company continues to maintain a credit rating of IND A- ; Positive assigned by India Ratings & Research, which was reaffirmed in December 2025. Further, at the request of the Company, CARE Ratings Limited has withdrawn the ratings earlier assigned to the Companys debt instruments.

Note: Subsequent to the finalisation of the Boards Report in August 2026, the rating was upgraded from IND A- to IND A.

13. Directors and Key Managerial Personnel

As on March 31, 2026, the Companys Board had eight members. This includes one Non-Executive Chairperson (Promoter Director), one Managing Director, one Non-Executive Non-Independent Director and five Non-Executive Independent Directors, one of whom is a Woman Independent Director.

Details about the Board, Committee composition, Director tenure and other details are available in the Corporate Governance Report, which is part of this Annual Report.

During the year, Colin Michael Bond (DIN: 10982819) was appointed as a Non-Executive Independent Director effective June 23, 2025 and also as Chairperson of Audit Committee effective from the said date. Approval of shareholders for his appointment was sought and obtained through Postal Ballot, the results of which were declared on July 31, 2025.

The details of the Board members as on March 31, 2026 is as below:

# Name of the Director	DIN	Designation
1. Arun Kumar	00084845	Chairperson, Non-Executive Director
2. Debarati Sen	07521172	Independent Director
3. Dr. Claudio Albrecht	10109819	Independent Director
4. Colin Michael Bond	10982819	Independent Director
5. Dr. Rashmi H. Barbhaiya	10593871	Independent Director
6. Vijay Paul Karwal	10905781	Independent Director
7. Bharat D. Shah	00136969	Non-Executive Director
8. Neeraj Sharma	09402652	Managing Director

Key Managerial Personnel (KMP):

In-terms of provisions of Section 2(51) and 203 of the Companies Act, 2013, the Company has the following Key Managerial Personnel (KMP) as at March 31, 2026 and as on date of this report:

# Name	Designation	Date of Appointment
1. Neeraj Sharma	Managing Director	March 01, 2024
2. Anurag Bhagania	Chief Financial Officer	July 04, 2024
3. Trisha Allada	Company Secretary	March 14, 2023

There were no changes in KMPs during the year.

14. Declaration by Independent Directors

The Company has received declarations from all Independent Directors in accordance with Section 149(7) of the Act read with Regulation 25(8) of the SEBI Listing Regulations confirming that they meet the criteria of independence as outlined in Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations. Further, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair their ability to discharge their duties with an independent judgment and without any external influence.

Additionally, the Independent Directors have declared their compliance with Section 150 of the Act read with Rules 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, regarding their inclusion in the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs. There have been no changes in the circumstances affecting their status as Independent Directors of the Company. In the opinion of the Board, the Independent Directors meet the conditions specified under the Act and the Listing Regulations.

15. Board Performance Evaluation

Evaluation of all Directors, Committees, Chairperson of the Board, and the Board as a whole was conducted for the year.

Evaluation process has been explained in Page 167 of the Corporate Governance Report, which forms part of this Annual Report.

16. Remuneration Policy and Criteria for Appointment of Directors

The percentage increase in remuneration, ratio of remuneration of Directors and Key Managerial Personnel (KMP) (as required under the Act) to the median of employees remuneration forms part of this report and is appended herewith as Annexure - 3 to this report.

Further, as per the provisions of Section 197(12) of the Act read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement containing names of top ten employees in terms of remuneration drawn and the particulars of employees employed throughout the year and in receipt of remuneration of _1.02 crore or more per annum and employees employed for part of the year and in receipt of remuneration of _8.50 lakh or more per month is to be provided.

However, in terms of the first proviso to Section 136(1) of the Act, the Annual Report, excluding the aforesaid information, is being sent to Shareholders of the Company and others entitled thereto.

The said information is available for inspection at the registered office of the Company up to the date of ensuing AGM. Shareholders interested in obtaining a copy may request the same by writing to the Company Secretary at cs@onesourcecdmo.com.

17. Board Diversity

Your Company recognises and embraces the importance of a diverse board in its success. The Board has adopted the Board Diversity Policy, which sets out the approach to the diversity of the Board of Directors. The said Policy is available on the Companys website at https://www.onesourcecdmo.com/wp-content/ uploads/2026/08/Board-Diversity-Policy.pdf.

18. Management Discussion and Analysis Report

The Management Discussion and Analysis Report as prescribed under Part B of Schedule V read with Regulation 34 of the Listing Regulations forms part of this Annual Report.

19. Corporate Governance Report

TheCorporateGovernanceReportalongwithacertificate on Corporate Governance from Vijayalakshmi K., Practicing Company Secretary, Bengaluru, for the FY26, forms part of this Annual Report.

20. Board Meetings

The Board of Directors of the Company met 6 (six) times during the year under review. The dates of the Board meetings and the attendance of the Directors at the meetings are provided in the Corporate Governance Report, which forms a part of this Annual Report.

21. Committees of the Board

As on March 31, 2026, the Board had the following Committees:

Statutory Committees: y Audit Committee (AC) y Nomination and Remuneration Committee (NRC) y Stakeholders Relationship Committee (SRC) y Risk Management Committee (RMC) y Corporate Social Responsibility Committee (CSR Committee)

Non-statutory Committees: y Strategic Advisory Committee y Scientific Advisory Committee y Environmental, Social, Governance (ESG) Committee y Management Committee The Corporate Governance Report, which forms part of this Annual Report, includes details about the meetings and composition of the Boards Statutory Committees.

22. Related Party Transactions

The Policy on Materiality of and dealing with Related Party Transactions, as approved by the Board, is available on the website of the Company at https://www.onesourcecdmo.com/wp-content/ uploads/2025/01/Policy-on-materiality-of-RPT.pdf As required under Section 134(3)(h) of the Act, details of transactions entered with related parties under the Act are given in Form AOC-2, provided as Annexure - 4 to this Report.

23. Whistle-blower Policy/Vigil Mechanism

The Company is committed to maintaining the highest standards of ethical, moral, and legal conduct in all its business operations. In line with this commitment, the Board of Directors has adopted a Whistle Blower Policy in compliance with the provisions of the Act and the SEBI Listing Regulations.

The Whistle Blower Policy provides an appropriate mechanism for directors, employees, and other stakeholders to make protected disclosures relating to actual or suspected violations, including financial irregularities, misrepresentation, fraud, theft, bribery, corrupt business practices, insider trading, and leak or suspected leak of unpublished price sensitive information, among others.

The Policy also sets out the procedures for receipt, tracking, investigation, and resolution of complaints, including disciplinary action, where warranted. Further, it provides safeguards to ensure confidentiality of the reporting process and protection of whistle blowers against any form of retaliation or victimization. Protected disclosures may be made through various channels, including email, submission of a physical letter, a designated toll free number operated by an independent third party, or through the SEEK Application (available to employees only), which is also operated by an independent third party.

The Audit Committee oversees the implementation and effective functioning of the Whistle Blower Policy, and no personnel of the Company have been denied direct access to the Audit Committee under this mechanism. Whistle Blower Policy is available on below link: https://www.onesourcecdmo.com/wp-content/ uploads/2025/07/Whistle-Blower-Policy.pdf.

24. Risk Management

The Board of Directors has established a Risk Management Committee to oversee the spectrum of organisational risks diligently. The Corporate Governance Report, an integral part of this document, provides detailed insights into the committees operations. The committee evaluates the effectiveness of risk mitigation strategies, ensuring they are robust and responsive.

25. Auditors a. Statutory Auditors

Pursuant to the provisions of Sections 139 and 142 of the Act read with the rules made thereunder, and the applicable provisions of the Listing Regulations, the term of appointment of the existing Statutory Auditors of the Company, M/s. Deloitte Haskins and Sells, shall conclude at the 19 th Annual General Meeting (AGM) of the Company.

Based on the evaluation and recommendation carried out by the management, M/s. B S R & Co. LLP has been proposed for appointment as the Statutory Auditors of the Company.

The proposal was placed before the Audit Committee, which, after due consideration, recommended the same to the Board of Directors. The Board recommends the appointment of M/s. B S R & Co. LLP as the Statutory Auditors of the Company to the approval of the Members at the ensuing AGM. b. Secretarial Auditors

The Secretarial Audit is conducted to verify compliance with the provisions of applicable laws, rules, regulations, guidelines and Secretarial Standards, thereby strengthening the Companys overall compliance framework.

Pursuant to the provisions of Section 204 of the Act, Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with Listing Regulations, the Shareholders in the AGM held on September 22, 2025, have approved the appointment of M/s. D V & Associates, Practicing Company Secretaries, as the Secretarial Auditors of the Company for a term of five (5) consecutive years, commencing from April 1, 2025, i.e., from FY 2025-26 to FY 2029-30.

The Secretarial Audit Report issued by the Secretarial Auditor in Form No. MR 3 is enclosed as Annexure - 5 to this Report. The said report does not contain any qualification, observation, reservation or adverse remark.

Further, pursuant to Regulation 24A of the Listing Regulations the Annual Secretarial Compliance Report for the financial year ended March 31, 2026, issued by the Secretarial Auditor, was submitted to the Stock Exchanges within the prescribed statutory timelines.

c. Internal Auditors

M/s. Grant Thornton Bharat LLP (formerly known as Grant Thornton India LLP) (LLPIN: AAA-7677) are the Internal Auditors of the Company.

During the year under review, Internal Auditors were satisfied with the management response on the observations and recommendations made by them during the course of their audit.

d. Cost Auditors

Pursuant to Section 148(1) of the Act, the Company is required to maintain cost records and accordingly such accounts and records were maintained for the financial year ending March 31, 2026.

26. Business Responsibility and Sustainability Report

The Business Responsibility and Sustainability Report of the Company for the year ended March 31, 2026 is provided in a separate section and forms part of this Annual Report.

27. Corporate Social Responsibility (CSR)

The Company is not mandatorily required to spend on CSR activities pursuant to the provisions of Section 135 of the Companies Act, 2013.

However, as per the conditions under the Karnataka Industrial Areas Development Board (KIADB) guidelines for OneSource: Unit 2, the Company is required to undertake CSR activities.

The Board has constituted a CSR Committee to monitor the aforesaid spend under KIADB guidelines.

Based on the recommendation of the said Committee, the Board has adopted a CSR policy that provides guiding principles for selection, implementation and monitoring of CSR activities and formulation of the annual action plan.

During the year, the Committee monitored the CSR activities undertaken by the Company including the expenditure incurred thereon as well as implementation and adherence to the CSR policy.

The CSR Policy of the Company is available on the website of the Company and can be accessed through the web link at: https://www.onesourcecdmo.com/wp-content/ uploads/2024/10/CSR-Policy-April-2022.pdf.

28. Conservation of Energy, Technology Absorption, and Foreign Exchange Earnings and Outgo

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated under Section 134(3)(m) of the Act read with Rule 8 of the Companies (Accounts) Rules, 2014, is provided as Annexure - 6 to this Report.

29. Disclosure of compliance with other statutory laws a. Disclosure under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The Company has zero tolerance for sexual harassment at workplace and has adopted a Policy on Prevention of Sexual Harassment in line with the requirements of The Sexual Harassment of Women at the workplace (Prevention, Prohibition

& Redressal) Act, 2013 (POSH Act) and Rules framed thereunder. OneSource has adopted a gender-neutral policy.

In compliance with the provisions of the POSH Act, Company has constituted Internal Complaints Committee (ICC) to redress complaints received on sexual harassment. Adequate trainings and awareness programmes against sexual harassment are conducted across the organisation to sensitise employees to uphold dignity of their colleagues and prevention of sexual harassment. During the financial year under review, the Company did not receive any complaints of sexual harassment. Consequently, there were no complaints disposed of during the year, and no complaints were pending for more than 90 days as at the end of the year.

b. Compliance with the Maternity Benefit Act, 1961

During the year under review, the company has duly complied with provisions of the Maternity Benefit Act, 1961 and all the facilities and support systems are in place to ensure a safe, secure, and inclusive working environment for women employees, in line with the requirements prescribed under Maternity Benefit Act, 1961 and relevant rules thereunder.

c. Number of employees as on March 31, 2026

i. Female	227
ii. Male	1,447
iii. Transgender	0
Total	1,674

d. Material Changes and Commitments

There have been no material changes and commitments affecting the Companys financial position between the end of the financial year and the date of this report other than those which have already been disclosed to the Stock Exchanges.

30. Cyber Security

Due to the rise in cyberattacks, we regularly review our cybersecurity practices and improve our processes and technology controls based on new threats. Our company has real-time security monitoring in place, along with necessary controls at different levels, from individual user devices to networks, servers, applications, and data.

31. Regulatory Orders

Currently, there are no substantial or material orders issued by regulatory bodies, courts, or tribunals that could affect the Companys capacity to continue as a going concern. According to the Listing Regulations, the Company is committed to transparently disclosing any significant events, important information, or regulatory directives it receives, ensuring that stakeholders are kept informed on a regular basis.

32. Annual Return

The draft Annual Return as required under sub-section (3) of Section 92 of the Act in form MGT-7 is made available on the website of the Company and can be accessed at https://www.onesourcecdmo.com/wp-content/uploads/2026/08/Annual-Return-1.pdf

33. Secretarial Standards

The Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India, as amended from time to time.

34. Unclaimed Shares Suspense Account

The Company, on December 10, 2024 had allotted equity shares to shareholders of Strides Pharma Science Limited (Strides) and Steriscience Specialties Private Limited (Steriscience) pursuant to the Scheme of Arrangement amongst the Company, Strides, and Steriscience.

The equity shares of the Company against the (1) IEPF account of Strides, (2) Letter of Confirmation cases of Strides, (3) Unclaimed Suspense account of Strides and (4) Shares held in physical form in Strides, were issued in demat form to corresponding suspense account opened by the Company with NSDL.

Details pertaining to Unpaid Shares Suspense account is provided in the Corporate Governance Report.

35. Other Disclosures

a. During the year under review, the Statutory Auditor,

Internal Auditor and Secretarial Auditor have not reported any instances of fraud committed in the Company by its Officers or Employees to the Audit Committee and/or Board under section 143(12) of the Act.

b. There are no proceedings initiated/pending against the Company under the Insolvency and Bankruptcy Code, 2016, and there is no instance of one-time settlement with any Bank or Financial Institution.

c. The Company has not issued any equity shares with differential rights regarding dividends, voting, or other rights.

d. There has been no change in the nature of the business of the Company during the financial year ended March 31, 2026.

36. Directors Responsibility Statement

Pursuant to the requirements under Section 134(5) read with Section 134(3)(c) of the Act, with respect to Directors Responsibility Statement, it is hereby confirmed that:

a. In the preparation of the annual accounts for the financial year ended March 31, 2026, the applicable accounting standards have been followed and there are no material departures from the same;

b. the Directors have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on March 31, 2026 and of the profit of the Company for the year ended on that date;

c. the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d. the Directors have prepared the annual accounts on a going concern basis;

e. the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and

f. the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

37. Acknowledgement

Your Directors take this opportunity to express their sincere gratitude to all employees, customers, and suppliers who have contributed to OneSource success over years. Their hard work, dedication, and support have been instrumental in achieving our goals and driving our business forward.

We would also like to thank our shareholders for their continued trust and investment in the Company. We are committed to build strong relationships with all our stakeholders, and we value their feedback and inputs as we strive to improve and grow our business. We look forward to your continued support in the years ahead.

For and on behalf of the Board of Directors

	Arun Kumar
	Chairperson,
Date: May 13, 2026	Non-Executive Director
Place: Bengaluru	DIN: 00084845